The ALS Better Care Act amends the Social Security Act to create a new Medicare benefit for outpatient ALS-related services and a single per-visit payment to qualified providers for patients medically determined to have amyotrophic lateral sclerosis. The bill defines a set of services (specialized physician or NP support, occupational/speech/physical therapy, dietary and respiratory support, RN support, and coordination of durable medical equipment) and makes coverage effective January 1, 2027.
The measure matters because it moves from fee-for-service fragmentation toward a condition-focused bundled payment intended to shore up specialized ALS clinics, encourage participation in clinical trials through payment adjustments, and expand remote management options. It also directs NINDS to report on clinical trial staffing and administrative barriers within 90 days of enactment — a signal this is as much about workforce and research capacity as it is about clinic reimbursement.
At a Glance
What It Does
Creates a new Medicare benefit category—'ALS-related services'—and a single supplemental payment per outpatient visit to qualified providers for covered ALS patients, effective Jan 1, 2027. The initial base payment is set at $800 for 2027 (with $800 or a GAO-recommended amount in 2028), then indexed by an ALS services market basket and subject to periodic Comptroller General recalibration.
Who It Affects
Medicare beneficiaries medically determined to have ALS, outpatient providers and clinics that furnish ALS care, CMS (for implementation and payments), and entities running ALS clinical trials that may receive a provider payment adjustment. The bill also triggers rulemaking to define 'qualified provider' and consultation requirements with ALS stakeholders.
Why It Matters
It creates a targeted reimbursement pathway aimed at stabilizing specialty ALS care delivery and supporting clinical research activity; the structure (bundled per-visit payment, no patient cost sharing, trial-related adders, and periodic GAO recalibration) will change how ALS clinics budget, bill, and participate in trials.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a narrowly defined set of outpatient items and services—named 'ALS-related services'—to the Medicare benefit package. Coverage is limited to individuals who are medically determined to have ALS under Medicare's existing standard and is available beginning January 1, 2027.
The listed services include clinical and therapy supports plus coordination for durable medical equipment; the list is intended to capture the multidisciplinary care ALS patients typically need.
For payment, the bill requires CMS to implement a single per-visit supplemental payment to a 'qualified provider' for those ALS-related services, paid in addition to any other Medicare payments. The statute sets an explicit baseline: a $800 payment for 2027, with $800 or a higher Comptroller General (GAO) recommended amount for 2028, and thereafter an annual update tied to an ALS services market basket percentage.
Every third year (beginning with 2030 as an 'applicable year') the GAO must submit a recalibration report that can replace the statutory update if its recommended amount is larger.The payment system must include adjustments: one to offset costs for qualified providers participating in clinical trials listed on clinicaltrials.gov, and another to account for new medical services or technologies whose costs are material relative to the bundled amount. CMS must accept claims that include the appropriate ICD–10–CM code for ALS and make payment on an assignment-related basis with no beneficiary cost sharing.
To be eligible for the payment, a provider must meet 'qualified provider' standards the Secretary will set by regulation after consultation with patients, clinicians, and ALS organizations.There are two implementation notes with operational impact: (1) CMS is authorized to implement most payment mechanics by program instruction, but the definition and requirements for 'qualified providers' require notice-and-comment rulemaking; and (2) a conforming change ensures outpatient department services provided to ALS patients remain payable even when the bundled payment applies. Separately, the bill tasks the Director of NINDS with a 90-day report identifying administrative and staffing challenges for ALS clinical trials and recommending actions, including potential legislative requests for appropriations.
The Five Things You Need to Know
Coverage for defined 'ALS-related services' begins January 1, 2027, and applies to Medicare beneficiaries medically determined to have ALS.
The statute establishes a single supplemental per-visit payment to qualified providers with a base amount of $800 for 2027 (and $800 or a higher GAO-recommended amount for 2028).
From 2029 forward the bundled payment is updated by an 'ALS services market basket' index, with the Comptroller General producing a recalibration report in applicable years (2030 and every third year thereafter) that can raise the payment.
Claims must include the ICD–10–CM code for ALS to trigger payment; CMS must pay on an assignment-related basis and the law prohibits beneficiary cost sharing for the bundled payment.
The payment system must include add-on adjustments for qualified providers participating in clinical trials listed on clinicaltrials.gov and for new services or technologies whose costs are substantial relative to the bundled amount.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Formalizes the bill's name as the 'ALS Better Care Act.' It's procedural but matters for references to the law in guidance, regulations, and subsequent appropriations or oversight.
Findings framing the policy problem
Lists congressional findings: ALS is progressive; multidisciplinary outpatient services improve outcomes; current Medicare reimbursement is inadequate; telehealth and clinical trial resourcing are important. These findings do not create legal rights but signal Congress's intent and provide the rationale agencies will cite when interpreting implementation rules and payment methodology.
Creates the 'ALS-related services' benefit and coverage trigger
Adds a new subsection defining the set of outpatient services that constitute ALS-related services and ties coverage to Medicare's medical determination of ALS (cross-referencing section 226(h)). Coverage is explicitly time-limited to services furnished on or after Jan 1, 2027. This is the statutory coverage hook that permits separate payment treatment under Medicare.
Establishes the single per-visit payment, indexing, and adjustments
Creates a new payment subsection requiring CMS to make a single supplemental payment to 'qualified providers' for ALS-related services furnished during a visit. It prescribes the initial dollar amounts, an indexing mechanism using an ALS services market basket, and a process for the Comptroller General to recommend recalibrated payment amounts every third year. It also mandates payment add-ons for providers participating in clinical trials and for costly new services/technologies, requires claims to include an ALS ICD–10–CM code, and prohibits beneficiary cost sharing for the supplemental payment.
Conforming payment language and 'qualified provider' rulemaking requirement
Makes technical adjustments so outpatient department services remain payable even when the bundled payment applies and amends the definition of 'arrangements' to include qualified providers for ALS-related services. Importantly, while most payment mechanics can be implemented by program instruction, the bill requires notice-and-comment rulemaking to define 'qualified provider' standards, and directs CMS to consult with patients, clinicians, and ALS organizations when writing those regulations.
NINDS report on ALS clinical trial administration and staffing
Directs the NINDS Director to submit a public report to Congress within 90 days of enactment identifying administrative and staffing barriers to ALS clinical trials, actions NINDS can take, and any legislative recommendations (including appropriation requests). This is a near-term deliverable aimed at informing workforce and funding policy for ALS research.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries medically determined to have ALS — Gain expanded, defined outpatient coverage and no-cost-sharing access to a package of multidisciplinary services and durable equipment coordination important to care and mobility.
- Specialized ALS clinics and multidisciplinary providers — Receive a predictable supplemental per-visit payment intended to stabilize revenue streams, reduce uncompensated care, and help sustain specialized staffing and telehealth infrastructure.
- Clinical researchers and trial sponsors — Benefit indirectly via an add-on payment for qualified providers participating in trials, which may lower the financial barrier for clinics to enroll patients and host research.
- Caregivers and families, especially in rural areas — Stand to see reduced travel burden and improved access because the statute recognizes telehealth and funds coordinated outpatient management that can replace some in-person needs.
- Patient advocacy organizations and ALS specialty societies — Obtain statutory recognition and a consultative role in CMS rulemaking for 'qualified providers,' increasing their influence on program design and quality standards.
Who Bears the Cost
- Medicare trust funds (and thus taxpayers) — Face increased outlays from the new bundled payments, indexing, and trial add-ons; the size of future costs will depend on utilization, indexing assumptions, and GAO recalibrations.
- CMS and Medicare administrative contractors — Must develop claims edits, payment logic, and oversight protocols for the new payment, plus run the consultations and rulemaking required to define 'qualified providers,' which will demand agency resources.
- Providers who do not meet 'qualified provider' criteria — May lose access to the supplemental payment and therefore face competitive disadvantage or pressure to pursue costly certification or consolidation to qualify.
- Smaller or rural practices — May incur compliance costs (billing systems, documentation, telehealth capability) to meet the provider requirements and participate for the bundled payment, even if they obtain some payment benefit.
- Medicare Advantage plans and commercial payers — Could experience spillover effects in pricing and network dynamics as Medicare establishes a new bundled payment and coverage baseline, potentially complicating managed care payment negotiations.
Key Issues
The Core Tension
The central dilemma is whether a narrowly targeted, higher reimbursement will successfully preserve specialized ALS care and expand trial participation without creating an expensive, administratively burdensome carve-out that can be mispriced or gamed; the bill solves access and funding shortfalls for ALS care but shifts difficult pricing, oversight, and implementation choices to agencies and auditors with no simple, guaranteed way to balance adequacy, fiscal restraint, and program integrity.
The bill creates a targeted bundled payment architecture but leaves key measurement and implementation choices to CMS and the Comptroller General. The ALS services market basket is undefined and will require CMS to select an 'appropriate mix' of items and services; different choices will materially change the annual update and the purchasing power of the bundled payment.
The Comptroller General's role—using historical high-utilization years across Medicare, private insurers, or MA plans to recommend a single payment—introduces methodological complexity and potential volatility when the GAO recommendation supersedes the statutory index in applicable years.
Operationally, the statute balances flexibility (allowing program instruction for many mechanics) with a mandatory rulemaking for the 'qualified provider' standard. That split risks faster technical deployment of payment logic but slower, contested regulatory definition of who may bill the new payment.
The ICD–10–CM code requirement is a practical claims trigger but creates an avenue for upcoding or disputes over whether a visit's services truly fall within ALS-related services. Finally, while the law forbids beneficiary cost sharing for the supplemental payment, it does not address how overlapping services billed under other Medicare provisions will be audited, reconciled, or prevented from duplicative payment beyond the technical conforming amendment.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.